Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
trending now
trending in pharma/biotech
trending in device
pharmagather
advertise
Legal Help
login/register
You are here
Home
»
companies
» Patisiran
Patisiran
Alnylam Submits NDA in Japan for Onpattro for Hereditary ATTR Amyloidosis
Alnylam Submits NDA in Japan for Onpattro for Hereditary ATTR Amyloidosis
CP Wire
Alnylam
Patisiran
Onpattro
Japan
hATTR amyloidosis
Flag link:
Alnylam Announces Encouraging Exploratory Cardiac Endpoint Data For Patisiran in hATTR Amyloidosis
Alnylam Announces Encouraging Exploratory Cardiac Endpoint Data For Patisiran in hATTR Amyloidosis
CP Wire
Alnylam
Patisiran
hATTR amyloidosis
Onpattro
Flag link:
Alnylam Announces Encouraging Exploratory Cardiac Endpoint Data For Patisiran in hATTR Amyloidosis
Alnylam
hATTR amyloidosis
Patisiran
Flag link:
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
Xconomy
RNAi
Alynylam
Europe
Onpattro
hATTR
Patisiran
Flag link:
After Alnylam’s solo maiden launch, here comes the tricky bit
After Alnylam’s solo maiden launch, here comes the tricky bit
EP Vantage
Alnylam
drug launches
FDA
RNAi
Patisiran
Onpattro
Flag link:
In first, FDA approves RNA interference drug from Alnylam
In first, FDA approves RNA interference drug from Alnylam
Biopharma Dive
Alnylam
RNAi
FDA
Patisiran
Onpattro
hATTR amyloidosis
Flag link:
With patisiran launch in its sights, Alnylam plots a major hiring spree
With patisiran launch in its sights, Alnylam plots a major hiring spree
Fierce Pharma
Alnylam
Patisiran
RNAi
hirings
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs
Yahoo/Benzinga
biotech
IPOs
Pain Therapeutics
Remoxy
Vertex Pharmaceuticals
lumacaftor/ivacaftor
Alnylam
Patisiran
Regeneron
Eylea
Insmed
Paratek
Vaccinex
Flag link:
Xconomy: Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
Xconomy: Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
Xconomy
FDA
Alynylam
Patisiran
hATTR amyloidosis
Flag link:
The UK's MHRA Grants Early Access to Anlylam's Patisiran
The UK's MHRA Grants Early Access to Anlylam's Patisiran
CP Wire
Alnylam
Patisiran
hATTR amyloidosis
UK
Flag link:
The UK's MHRA Grants Early Access to Anlylam's Patisiran
Alnylam
Patisiran
hATTR amyloidosis
Flag link:
Alnylam Receives Positive CHMP Opinion for Hereditary Amyloidosis Treatment
Alnylam Receives Positive CHMP Opinion for Hereditary Amyloidosis Treatment
CP Wire
Alnylam
Patisiran
EMA
hATTR amyloidosis
Flag link:
Alnylam Receives Positive CHMP Opinion for Hereditary Amyloidosis Treatment
Alnylam
Patisiran
hATTR amyloidosis
Flag link:
Alnylam Presents Ph III results of Patisiran in Hereditary ATTR (hATTR) Amyloidosis
Alnylam Presents Ph III results of Patisiran in Hereditary ATTR (hATTR) Amyloidosis
CP Wire
Alnylam
Patisiran
hereditary ATTR amyloidosis
Flag link:
Alnylam Presents Ph III results of Patisiran in Hereditary ATTR (hATTR) Amyloidosis
Alnylam
hereditary ATTR amyloidosis
Patisiran
Flag link:
FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead
FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead
CP Wire
Akcea
hereditary ATTR amyloidosis
FDA
inotersen
Alnylam
Patisiran
Flag link:
FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead
Akcea Therapeutics
inotersen
Alnylam
Patisiran
Flag link:
Why Pfizer's Big Win Is Bad News for Alnylam and Ionis
Why Pfizer's Big Win Is Bad News for Alnylam and Ionis
Yahoo/Motley Fool
Pfizer
Alnylam
Ionis Pharmaceuticals
tafamidis
inotersen
Patisiran
Flag link:
3 Blockbuster Drug Launches to Watch In 2018
3 Blockbuster Drug Launches to Watch In 2018
Motley Fool
drug launches
Gilead Sciences
HIV
Biktarvy
Alnylam
Sanofi
Patisiran
Epidiolex
GW Pharma
Flag link:
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
drug launches
Hemlibra
Roche
Biktarvy
Gilead Sciences
Ozempic
Novo Nordisk
Erleada
JNJ
Shingrix
GSK
Patisiran
Alnylam
Sanofi
Epidiolex
GW Pharma
Aimovig
Amgen
Novartis
lanadelumab
Shire
Elagolix
AbbVie
Steglatro
Pfizer
Merck
Sublocade
Indivior
Flag link:
Pages
1
2
next ›
last »